Essential Strategies for Eliminating HCV Among Persons With Current or Recent Injection Drug Use

HCV Elimination 2019 Program Image
This interactive video module provides in-depth expert perspectives on critical barriers impeding the diagnosis, treatment, and cure of HCV infection among persons who inject drugs along with an analysis of critical strategies for overcoming these challenges to address both HCV and other important healthcare needs of this vulnerable population.
Mark S. Sulkowski, MD
Program Director
Arthur Kim, MD
Christian Ramers Headshot
Christian B. Ramers, MD, MPH
Jeannette M. Tetrault, MD, FACP, FASAM
Released: April 2, 2019 Expiration: No longer available for credit

Related Content

Downloadable slides from CCO expert, Dr. Alain H. Litwin, on integrating HCV and HIV prevention and care strategies into addiction care settings

Alain H. Litwin, MD Released: September 18, 2020

Dr. Stefan Zeuzem discusses new viral hepatitis data reported at the 2020 Digital International Liver Congress, in the CCO Infectious Disease podcast

Stefan Zeuzem, MD Released: September 14, 2020

Expert selections of the most important viral hepatitis data from EASL 2020, including HCV elimination and HCV and HBV treatment, provided by CCO

Stefan Zeuzem, MD Released: September 8, 2020

Downloadable PDF resource from CCO on opioid use disorder treatment essentials for hepatologists and ID specialists managing HCV and/or HIV infection

Jenna Butner, MD Released: May 7, 2020
Jointly provided by

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Endorsed by
This activity is supported by independent educational grants from
AbbVie
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue